Aberrant NF-kB signaling has been shown to affect resistance to ibrutinib plus venetoclax combination therapy in CLL cells by increasing MCL-1 and BCL-xL expression [124]. Here, MCL1 is linked to B-cell chronic lymphocytic leukemia.